SK187899A3 - Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches - Google Patents

Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches Download PDF

Info

Publication number: SK187899A3
Authority: SK; Slovakia
Prior art keywords: headache; local anesthetic; patient; administration; pain
Prior art date: 1997-07-21

Application number

SK1878-99A

Other languages

English (en)

Slovak (sk)

Inventor

Bruce H Levin

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-21

Filing date

1998-07-17

Publication date

2000-12-11

1998-07-17 Application filed by Astra Ab filed Critical Astra Ab

2000-12-11 Publication of SK187899A3 publication Critical patent/SK187899A3/sk

Links

206010019233 Headaches Diseases 0.000 title claims abstract description 349
231100000869 headache Toxicity 0.000 title claims abstract description 337
230000003387 muscular Effects 0.000 title claims abstract description 108
239000000203 mixture Substances 0.000 title abstract description 253
238000000034 method Methods 0.000 title abstract description 165
230000002490 cerebral effect Effects 0.000 title abstract description 54
230000002401 inhibitory effect Effects 0.000 title abstract description 45
208000017376 neurovascular disease Diseases 0.000 title abstract description 14
239000003589 local anesthetic agent Substances 0.000 claims abstract description 309
206010027599 migraine Diseases 0.000 claims abstract description 152
208000019695 Migraine disease Diseases 0.000 claims abstract description 132
239000003814 drug Substances 0.000 claims abstract description 41
206010043269 Tension headache Diseases 0.000 claims abstract description 10
208000008548 Tension-Type Headache Diseases 0.000 claims abstract description 10
238000004519 manufacturing process Methods 0.000 claims abstract description 5
ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 152
229960001549 ropivacaine Drugs 0.000 claims description 152
238000011282 treatment Methods 0.000 claims description 100
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 55
229960003150 bupivacaine Drugs 0.000 claims description 54
230000003444 anaesthetic effect Effects 0.000 claims description 53
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 52
229960001340 histamine Drugs 0.000 claims description 28
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 1
229960004288 levobupivacaine Drugs 0.000 claims 1
208000019553 vascular disease Diseases 0.000 claims 1
241000282414 Homo sapiens Species 0.000 abstract description 63
239000008194 pharmaceutical composition Substances 0.000 abstract description 55
239000013543 active substance Substances 0.000 abstract description 41
238000012384 transportation and delivery Methods 0.000 abstract description 27
230000004118 muscle contraction Effects 0.000 abstract description 15
241001465754 Metazoa Species 0.000 abstract description 9
239000003937 drug carrier Substances 0.000 abstract description 7
239000004615 ingredient Substances 0.000 abstract description 5
208000006561 Cluster Headache Diseases 0.000 abstract description 3
208000018912 cluster headache syndrome Diseases 0.000 abstract description 3
208000002193 Pain Diseases 0.000 description 162
230000036407 pain Effects 0.000 description 162
208000024891 symptom Diseases 0.000 description 98
150000001875 compounds Chemical class 0.000 description 80
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 64
229960004194 lidocaine Drugs 0.000 description 63
229960005015 local anesthetics Drugs 0.000 description 62
230000001154 acute effect Effects 0.000 description 60
210000005036 nerve Anatomy 0.000 description 56
238000009472 formulation Methods 0.000 description 55
210000001519 tissue Anatomy 0.000 description 54
206010002091 Anaesthesia Diseases 0.000 description 52
230000037005 anaesthesia Effects 0.000 description 52
230000000694 effects Effects 0.000 description 49
230000002085 persistent effect Effects 0.000 description 46
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 38
210000002850 nasal mucosa Anatomy 0.000 description 34
208000009205 Tinnitus Diseases 0.000 description 33
-1 ergot Chemical compound 0.000 description 33
239000007921 spray Substances 0.000 description 32
231100000886 tinnitus Toxicity 0.000 description 31
229940079593 drug Drugs 0.000 description 29
230000000306 recurrent effect Effects 0.000 description 27
229920000742 Cotton Polymers 0.000 description 26
230000000302 ischemic effect Effects 0.000 description 26
239000007787 solid Substances 0.000 description 25
230000000699 topical effect Effects 0.000 description 24
230000005764 inhibitory process Effects 0.000 description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
210000003928 nasal cavity Anatomy 0.000 description 22
239000012730 sustained-release form Substances 0.000 description 22
238000013268 sustained release Methods 0.000 description 21
230000009885 systemic effect Effects 0.000 description 21
230000001965 increasing effect Effects 0.000 description 20
230000001537 neural effect Effects 0.000 description 20
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 20
229960003920 cocaine Drugs 0.000 description 19
208000035475 disorder Diseases 0.000 description 19
230000009467 reduction Effects 0.000 description 18
229960003708 sumatriptan Drugs 0.000 description 18
238000012385 systemic delivery Methods 0.000 description 18
230000002792 vascular Effects 0.000 description 18
208000003098 Ganglion Cysts Diseases 0.000 description 17
208000005400 Synovial Cyst Diseases 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 17
206010028813 Nausea Diseases 0.000 description 16
239000012530 fluid Substances 0.000 description 16
210000003128 head Anatomy 0.000 description 16
210000003205 muscle Anatomy 0.000 description 16
230000008693 nausea Effects 0.000 description 16
239000000243 solution Substances 0.000 description 16
206010034960 Photophobia Diseases 0.000 description 15
239000000952 serotonin receptor agonist Substances 0.000 description 15
239000005526 vasoconstrictor agent Substances 0.000 description 15
238000010521 absorption reaction Methods 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
238000007917 intracranial administration Methods 0.000 description 14
239000000126 substance Substances 0.000 description 14
238000002560 therapeutic procedure Methods 0.000 description 14
239000006196 drop Substances 0.000 description 13
238000005192 partition Methods 0.000 description 13
230000004044 response Effects 0.000 description 13
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
108091006146 Channels Proteins 0.000 description 12
208000001286 intracranial vasospasm Diseases 0.000 description 12
230000008569 process Effects 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
230000007423 decrease Effects 0.000 description 11
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
230000024883 vasodilation Effects 0.000 description 11
206010059109 Cerebral vasoconstriction Diseases 0.000 description 10
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 10
230000017531 blood circulation Effects 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229940097496 nasal spray Drugs 0.000 description 10
239000007922 nasal spray Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
208000007920 Neurogenic Inflammation Diseases 0.000 description 9
206010047163 Vasospasm Diseases 0.000 description 9
230000001684 chronic effect Effects 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
210000000981 epithelium Anatomy 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
208000028867 ischemia Diseases 0.000 description 9
230000007246 mechanism Effects 0.000 description 9
230000035790 physiological processes and functions Effects 0.000 description 9
206010001497 Agitation Diseases 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 8
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
239000000556 agonist Substances 0.000 description 8
230000008602 contraction Effects 0.000 description 8
230000006378 damage Effects 0.000 description 8
230000004438 eyesight Effects 0.000 description 8
FCQJEPASRCXVCB-UHFFFAOYSA-N flavianic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FCQJEPASRCXVCB-UHFFFAOYSA-N 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
230000000926 neurological effect Effects 0.000 description 8
ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
210000003901 trigeminal nerve Anatomy 0.000 description 8
230000000304 vasodilatating effect Effects 0.000 description 8
230000000007 visual effect Effects 0.000 description 8
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
229930182837 (R)-adrenaline Natural products 0.000 description 7
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
206010010904 Convulsion Diseases 0.000 description 7
208000037048 Prodromal Symptoms Diseases 0.000 description 7
230000000202 analgesic effect Effects 0.000 description 7
238000009826 distribution Methods 0.000 description 7
238000012377 drug delivery Methods 0.000 description 7
229960005139 epinephrine Drugs 0.000 description 7
229960003692 gamma aminobutyric acid Drugs 0.000 description 7
230000001976 improved effect Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
230000005906 menstruation Effects 0.000 description 7
229940100662 nasal drops Drugs 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
230000001953 sensory effect Effects 0.000 description 7
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
208000005392 Spasm Diseases 0.000 description 6
229960001138 acetylsalicylic acid Drugs 0.000 description 6
230000036592 analgesia Effects 0.000 description 6
239000002876 beta blocker Substances 0.000 description 6
229940097320 beta blocking agent Drugs 0.000 description 6
230000005540 biological transmission Effects 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 6
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
238000011260 co-administration Methods 0.000 description 6
230000005496 eutectics Effects 0.000 description 6
239000000835 fiber Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
230000001771 impaired effect Effects 0.000 description 6
239000003158 myorelaxant agent Substances 0.000 description 6
239000007923 nasal drop Substances 0.000 description 6
229960000425 rizatriptan Drugs 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
230000001457 vasomotor Effects 0.000 description 6
VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
206010047139 Vasoconstriction Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000009471 action Effects 0.000 description 5
230000002411 adverse Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
229960003976 etidocaine Drugs 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000002502 liposome Substances 0.000 description 5
210000004228 maxillary nerve Anatomy 0.000 description 5
230000003533 narcotic effect Effects 0.000 description 5
210000001331 nose Anatomy 0.000 description 5
229960005489 paracetamol Drugs 0.000 description 5
238000011160 research Methods 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
238000007910 systemic administration Methods 0.000 description 5
230000025033 vasoconstriction Effects 0.000 description 5
ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 5
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
208000014604 Specific Language disease Diseases 0.000 description 4
229940123445 Tricyclic antidepressant Drugs 0.000 description 4
239000002250 absorbent Substances 0.000 description 4
230000002745 absorbent Effects 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
201000007201 aphasia Diseases 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000002146 bilateral effect Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000036770 blood supply Effects 0.000 description 4
230000003727 cerebral blood flow Effects 0.000 description 4
210000004889 cervical nerve Anatomy 0.000 description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
238000004891 communication Methods 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000006260 foam Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
210000001847 jaw Anatomy 0.000 description 4
230000013016 learning Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000001589 microsome Anatomy 0.000 description 4
239000002858 neurotransmitter agent Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
230000001734 parasympathetic effect Effects 0.000 description 4
230000007170 pathology Effects 0.000 description 4
229960000482 pethidine Drugs 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
230000005855 radiation Effects 0.000 description 4
210000004761 scalp Anatomy 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
210000002027 skeletal muscle Anatomy 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
230000002889 sympathetic effect Effects 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000032258 transport Effects 0.000 description 4
239000003029 tricyclic antidepressant agent Substances 0.000 description 4
ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
229960001360 zolmitriptan Drugs 0.000 description 4
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
241001535291 Analges Species 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
208000007101 Muscle Cramp Diseases 0.000 description 3
AWEZYKMQFAUBTD-UHFFFAOYSA-N Naratriptan hydrochloride Chemical compound [H+].[Cl-].C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AWEZYKMQFAUBTD-UHFFFAOYSA-N 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 3
125000000266 alpha-aminoacyl group Chemical group 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
210000003484 anatomy Anatomy 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
229940049706 benzodiazepine Drugs 0.000 description 3
230000002051 biphasic effect Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 3
229960001590 butorphanol tartrate Drugs 0.000 description 3
229960001948 caffeine Drugs 0.000 description 3
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
239000000480 calcium channel blocker Substances 0.000 description 3
210000001326 carotid sinus Anatomy 0.000 description 3
210000000711 cavernous sinus Anatomy 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
230000010339 dilation Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000002173 dizziness Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
229960004943 ergotamine Drugs 0.000 description 3
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 3
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
239000000374 eutectic mixture Substances 0.000 description 3
230000005284 excitation Effects 0.000 description 3
229960002870 gabapentin Drugs 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
230000002045 lasting effect Effects 0.000 description 3
229910001416 lithium ion Inorganic materials 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910001425 magnesium ion Inorganic materials 0.000 description 3
238000002483 medication Methods 0.000 description 3
229960002409 mepivacaine Drugs 0.000 description 3
210000002161 motor neuron Anatomy 0.000 description 3
210000004126 nerve fiber Anatomy 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
229960001802 phenylephrine Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000001044 sensory neuron Anatomy 0.000 description 3
208000018316 severe headache Diseases 0.000 description 3
230000012232 skeletal muscle contraction Effects 0.000 description 3
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
238000005728 strengthening Methods 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
229960002372 tetracaine Drugs 0.000 description 3
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
229940102566 valproate Drugs 0.000 description 3
229940124549 vasodilator Drugs 0.000 description 3
239000003071 vasodilator agent Substances 0.000 description 3
229960001722 verapamil Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Chemical class C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
208000028698 Cognitive impairment Diseases 0.000 description 2
206010013952 Dysphonia Diseases 0.000 description 2
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical class C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000010428 Muscle Weakness Diseases 0.000 description 2
206010028372 Muscular weakness Diseases 0.000 description 2
241000237536 Mytilus edulis Species 0.000 description 2
206010028836 Neck pain Diseases 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
206010054956 Phonophobia Diseases 0.000 description 2
206010039729 Scotoma Diseases 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
208000028911 Temporomandibular Joint disease Diseases 0.000 description 2
206010043220 Temporomandibular joint syndrome Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001467 acupuncture Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
208000030961 allergic reaction Diseases 0.000 description 2
229940035674 anesthetics Drugs 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 2
229960002546 butalbital Drugs 0.000 description 2
229960001113 butorphanol Drugs 0.000 description 2
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
229960005233 cineole Drugs 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
238000009223 counseling Methods 0.000 description 2
229960000265 cromoglicic acid Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical class O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical class [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
229940028937 divalproex sodium Drugs 0.000 description 2
230000005670 electromagnetic radiation Effects 0.000 description 2
230000003073 embolic effect Effects 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
210000000256 facial nerve Anatomy 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
210000003746 feather Anatomy 0.000 description 2
208000013088 frontal headache Diseases 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
229940090436 imitrex Drugs 0.000 description 2
239000007943 implant Substances 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
229940103177 maxalt Drugs 0.000 description 2
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
229940035363 muscle relaxants Drugs 0.000 description 2
235000020638 mussel Nutrition 0.000 description 2
229960005254 naratriptan Drugs 0.000 description 2
239000004081 narcotic agent Substances 0.000 description 2
239000004084 narcotic analgesic agent Substances 0.000 description 2
229940029571 naropin Drugs 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
230000008035 nerve activity Effects 0.000 description 2
230000007433 nerve pathway Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000002182 neurohumoral effect Effects 0.000 description 2
230000007971 neurological deficit Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
210000003300 oropharynx Anatomy 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
229960001807 prilocaine Drugs 0.000 description 2
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000011514 reflex Effects 0.000 description 2
NBFQYHKHPBMJJV-UHFFFAOYSA-N risocaine Chemical compound CCCOC(=O)C1=CC=C(N)C=C1 NBFQYHKHPBMJJV-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical class NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 2
RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Chemical class NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 2
230000028327 secretion Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000005507 spraying Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
231100000057 systemic toxicity Toxicity 0.000 description 2
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical class O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Chemical class C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
229950010357 tetrodotoxin Drugs 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229940125725 tranquilizer Drugs 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
230000002936 tranquilizing effect Effects 0.000 description 2
238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
230000006442 vascular tone Effects 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
230000002455 vasospastic effect Effects 0.000 description 2
208000029257 vision disease Diseases 0.000 description 2
230000004393 visual impairment Effects 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical class C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
HZGRVVUQEIBCMS-HTRCEHHLSA-N (1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene-4-carboxylic acid Chemical compound C1C=C(C(O)=O)[C@H]2CC[C@@H]1N2C HZGRVVUQEIBCMS-HTRCEHHLSA-N 0.000 description 1
KRCGPQRORHRZRC-SXWHKFHYSA-N (2s)-2-hydroxybutanedioic acid;(1s)-1-phenyl-2-pyridin-2-ylethanamine Chemical compound OC(=O)[C@@H](O)CC(O)=O.C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 KRCGPQRORHRZRC-SXWHKFHYSA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
ZLMQPGUWYWFPEG-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate Chemical compound CCCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC ZLMQPGUWYWFPEG-UHFFFAOYSA-N 0.000 description 1
QNIUOGIMJWORNZ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-butoxybenzoate Chemical compound CCCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 QNIUOGIMJWORNZ-UHFFFAOYSA-N 0.000 description 1
XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 1
JVKVEOKPRHZKNW-UHFFFAOYSA-N 2-hydroxybenzoic acid;hydrate Chemical compound O.OC(=O)C1=CC=CC=C1O JVKVEOKPRHZKNW-UHFFFAOYSA-N 0.000 description 1
PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000002381 Brain Hypoxia Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
206010064012 Central pain syndrome Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020802 Hypertensive crisis Diseases 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
206010033474 Pain of skin Diseases 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
229920001363 Polidocanol Polymers 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
206010040744 Sinus headache Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
206010042618 Surgical procedure repeated Diseases 0.000 description 1
101150095095 TIMELESS gene Proteins 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000010641 Tooth disease Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000001407 Vascular Headaches Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
208000013521 Visual disease Diseases 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
RFPVXZWXDPIKSD-UHFFFAOYSA-N [2-(diethylamino)-4-methylpentyl] 4-aminobenzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCN(CC)C(CC(C)C)COC(=O)C1=CC=C(N)C=C1 RFPVXZWXDPIKSD-UHFFFAOYSA-N 0.000 description 1
VPRGXNLHFBBDFS-UHFFFAOYSA-N [3-(diethylamino)-1-phenylpropyl] benzoate Chemical compound C=1C=CC=CC=1C(CCN(CC)CC)OC(=O)C1=CC=CC=C1 VPRGXNLHFBBDFS-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
229950008211 ambucaine Drugs 0.000 description 1
229940067621 aminobutyrate Drugs 0.000 description 1
HPITVGRITATAFY-UHFFFAOYSA-N amolanone Chemical compound O=C1OC2=CC=CC=C2C1(CCN(CC)CC)C1=CC=CC=C1 HPITVGRITATAFY-UHFFFAOYSA-N 0.000 description 1
229950009452 amolanone Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000003459 anti-dromic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000003464 asthenopia Diseases 0.000 description 1
230000001042 autoregulative effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000008316 benzisoxazoles Chemical class 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
229950005028 betoxycaine Drugs 0.000 description 1
CXYOBRKOFHQONJ-UHFFFAOYSA-N betoxycaine Chemical compound CCCCOC1=CC=C(C(=O)OCCOCCN(CC)CC)C=C1N CXYOBRKOFHQONJ-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
229960000400 butamben Drugs 0.000 description 1
229960002463 butoxycaine Drugs 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
229960004741 cyclomethycaine Drugs 0.000 description 1
PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 1
230000006837 decompression Effects 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000013527 degreasing agent Substances 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229950010160 dimethocaine Drugs 0.000 description 1
OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000005553 drilling Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
229960000385 dyclonine Drugs 0.000 description 1
PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
229960003750 ethyl chloride Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
238000005187 foaming Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
206010019465 hemiparesis Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
DHCUQNSUUYMFGX-UHFFFAOYSA-N hydroxytetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C(O)=C1 DHCUQNSUUYMFGX-UHFFFAOYSA-N 0.000 description 1
229950000638 hydroxytetracaine Drugs 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
229960005287 lincomycin Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000000627 locus coeruleus Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
229950007594 meprylcaine Drugs 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
229950004316 metabutoxycaine Drugs 0.000 description 1
ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000023105 myelination Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000492 nasalseptum Anatomy 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
230000026536 negative regulation of muscle contraction Effects 0.000 description 1
230000007372 neural signaling Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000008587 neuronal excitability Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
229940052264 other local anesthetics in atc Drugs 0.000 description 1
229960003502 oxybuprocaine Drugs 0.000 description 1
CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
238000002559 palpation Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
BMIJYAZXNZEMLI-UHFFFAOYSA-N piridocaine Chemical compound NC1=CC=CC=C1C(=O)OCCC1NCCCC1 BMIJYAZXNZEMLI-UHFFFAOYSA-N 0.000 description 1
229950001038 piridocaine Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
229960002226 polidocanol Drugs 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229960001896 pramocaine Drugs 0.000 description 1
DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229950008865 propanocaine Drugs 0.000 description 1
229960003981 proparacaine Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
229950011219 propipocaine Drugs 0.000 description 1
229950003255 propoxycaine Drugs 0.000 description 1
230000009023 proprioceptive sensation Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229960005038 quinisocaine Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000004189 reticular formation Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229950003447 risocaine Drugs 0.000 description 1
239000011435 rock Substances 0.000 description 1
CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
TYWUGCGYWNSRPS-UHFFFAOYSA-N sameridine Chemical compound C1CN(CCCCCC)CCC1(C(=O)N(C)CC)C1=CC=CC=C1 TYWUGCGYWNSRPS-UHFFFAOYSA-N 0.000 description 1
229950000028 sameridine Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 description 1
229950006609 tolycaine Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
210000000427 trigeminal ganglion Anatomy 0.000 description 1
GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
229950002569 trimecaine Drugs 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
229940072651 tylenol Drugs 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
229940045136 urea Drugs 0.000 description 1
210000002396 uvula Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 description 1
229950006211 zolamine Drugs 0.000 description 1
229940003675 zomig Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1878-99A 1997-07-21 1998-07-17 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches SK187899A3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US89719297A	1997-07-21	1997-07-21
US7284598P	1998-01-28	1998-01-28
US8455998P	1998-05-06	1998-05-06
PCT/US1998/014870 WO1999003473A1 (en)	1997-07-21	1998-07-17	Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches

Publications (1)

Publication Number	Publication Date
SK187899A3 true SK187899A3 (en)	2000-12-11

Family

ID=27372174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1878-99A SK187899A3 (en)	1997-07-21	1998-07-17	Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches

Country Status (20)

Country	Link
EP (1)	EP0999839B1 (xx)
JP (1)	JP4521117B2 (xx)
KR (1)	KR20010022041A (xx)
CN (1)	CN1267219A (xx)
AR (1)	AR013240A1 (xx)
AT (1)	ATE269702T1 (xx)
AU (1)	AU8574398A (xx)
BR (1)	BR9810773A (xx)
CA (1)	CA2297097C (xx)
DE (1)	DE69824730T2 (xx)
EE (1)	EE200000050A (xx)
HU (1)	HUP0003953A3 (xx)
ID (1)	ID24903A (xx)
IL (2)	IL134087A0 (xx)
IS (1)	IS5349A (xx)
NO (1)	NO20000293L (xx)
PL (1)	PL338176A1 (xx)
SK (1)	SK187899A3 (xx)
TR (1)	TR200000149T2 (xx)
WO (1)	WO1999003473A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9704349D0 (en) *	1997-03-03	1997-04-23	Chiroscience Ltd	Levobupivacaine and its use
JP4632499B2 (ja) *	1999-08-26	2011-02-16	武田薬品工業株式会社	鼻粘膜付着マトリックス
WO2001043733A2 (en) *	1999-12-15	2001-06-21	Levin Bruce H	Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
GB9930083D0 (en) *	1999-12-20	2000-02-09	Glaxo Group Ltd	Medicaments
US7146209B2 (en)	2000-05-08	2006-12-05	Brainsgate, Ltd.	Stimulation for treating eye pathologies
US6853858B2 (en)	2000-05-08	2005-02-08	Brainsgate, Ltd.	Administration of anti-inflammatory drugs into the central nervous system
US7117033B2 (en)	2000-05-08	2006-10-03	Brainsgate, Ltd.	Stimulation for acute conditions
WO2001085094A2 (en)	2000-05-08	2001-11-15	Brainsgate Ltd.	Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow
US7640062B2 (en)	2000-05-08	2009-12-29	Brainsgate Ltd.	Methods and systems for management of alzheimer's disease
JP2006515999A (ja)	2002-11-14	2006-06-15	ブレインズゲートリミティド	刺激のための外科用ツール及び技法
US7561919B2 (en)	2002-11-14	2009-07-14	Brainsgate Ltd.	SPG stimulation via the greater palatine canal
US7769461B2 (en)	2003-12-19	2010-08-03	Boston Scientific Neuromodulation Corporation	Skull-mounted electrical stimulation system and method for treating patients
US9233245B2 (en)	2004-02-20	2016-01-12	Brainsgate Ltd.	SPG stimulation
US8055347B2 (en)	2005-08-19	2011-11-08	Brainsgate Ltd.	Stimulation for treating brain events and other conditions
US8010189B2 (en)	2004-02-20	2011-08-30	Brainsgate Ltd.	SPG stimulation for treating complications of subarachnoid hemorrhage
WO2006018997A1 (ja) *	2004-08-18	2006-02-23	Medrx Co., Ltd.	外用剤
CN104352429B (zh) *	2008-07-21	2018-05-18	奥德纳米有限公司	用于治疗耳部病症的受控释放抗微生物组合物和方法
DE102008037682A1 (de)	2008-08-14	2010-04-08	Strackharn, Klaus, Dr.med.	Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
AU2013323246A1 (en)	2012-09-28	2015-04-16	St. Renatus, Llc	Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
CN103432378A (zh) *	2013-08-15	2013-12-11	吕清华	一种治疗神经血管性头痛的中药
US9675796B2 (en)	2013-11-10	2017-06-13	Brainsgate Ltd.	Implant and delivery system for neural stimulator
EP3093043B1 (en)	2015-05-13	2018-11-14	Brainsgate Ltd.	Implant and delivery system for neural stimulator
CN113573705A (zh) *	2018-12-19	2021-10-29	诺迪克控股公司	鼻内利多卡因的治疗组合物
EP3914246A1 (en) *	2019-01-22	2021-12-01	ICM (Institut du Cerveau et de la Moelle Épinière)	Local anesthetic for the treatment of neurological symptoms resulting from brain dysfunctions
GB2628149A (en) *	2023-03-16	2024-09-18	Lee Nathaniel Wurie	Nasal spray for performing sphenopalatine ganglion block

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9321061D0 (en) *	1993-10-13	1993-12-01	Chiroscience Ltd	Analgestic agent and its use
DE19524691A1 (de) *	1995-07-06	1997-01-09	Liedtke Pharmed Gmbh	Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
DE19526019A1 (de) *	1995-07-17	1997-01-23	Liedtke Pharmed Gmbh	Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen
BE1009851A3 (fr) *	1996-01-11	1997-10-07	Thiebauld Charles Marie	Composition pharmaceutique pour le traitement des cephalees et son utilisation.
GB2315673A (en) *	1996-08-01	1998-02-11	Merck & Co Inc	Treatment of migraine
US5891885A (en) *	1996-10-09	1999-04-06	Algos Pharmaceutical Corporation	Method for treating migraine
GB9704349D0 (en) *	1997-03-03	1997-04-23	Chiroscience Ltd	Levobupivacaine and its use

1998
- 1998-07-17 BR BR9810773-9A patent/BR9810773A/pt not_active IP Right Cessation
- 1998-07-17 AU AU85743/98A patent/AU8574398A/en not_active Abandoned
- 1998-07-17 CN CN98808214A patent/CN1267219A/zh active Pending
- 1998-07-17 SK SK1878-99A patent/SK187899A3/sk unknown
- 1998-07-17 DE DE69824730T patent/DE69824730T2/de not_active Expired - Lifetime
- 1998-07-17 WO PCT/US1998/014870 patent/WO1999003473A1/en not_active Ceased
- 1998-07-17 ID IDW20000123D patent/ID24903A/id unknown
- 1998-07-17 HU HU0003953A patent/HUP0003953A3/hu unknown
- 1998-07-17 CA CA002297097A patent/CA2297097C/en not_active Expired - Lifetime
- 1998-07-17 EE EEP200000050A patent/EE200000050A/xx unknown
- 1998-07-17 PL PL98338176A patent/PL338176A1/xx unknown
- 1998-07-17 TR TR2000/00149T patent/TR200000149T2/xx unknown
- 1998-07-17 IL IL13408798A patent/IL134087A0/xx active IP Right Grant
- 1998-07-17 AT AT98936893T patent/ATE269702T1/de not_active IP Right Cessation
- 1998-07-17 JP JP2000502772A patent/JP4521117B2/ja not_active Expired - Fee Related
- 1998-07-17 EP EP98936893A patent/EP0999839B1/en not_active Expired - Lifetime
- 1998-07-17 KR KR1020007000610A patent/KR20010022041A/ko not_active Withdrawn
- 1998-07-21 AR ARP980103565A patent/AR013240A1/es unknown
2000
- 2000-01-17 IL IL134087A patent/IL134087A/en not_active IP Right Cessation
- 2000-01-18 IS IS5349A patent/IS5349A/is unknown
- 2000-01-20 NO NO20000293A patent/NO20000293L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL134087A (en)	2006-10-31
DE69824730D1 (de)	2004-07-29
WO1999003473A1 (en)	1999-01-28
EP0999839A1 (en)	2000-05-17
HUP0003953A1 (hu)	2002-01-28
IS5349A (is)	2000-01-18
CN1267219A (zh)	2000-09-20
ID24903A (id)	2000-08-31
EE200000050A (et)	2000-10-16
EP0999839B1 (en)	2004-06-23
NO20000293D0 (no)	2000-01-20
TR200000149T2 (tr)	2000-05-22
HUP0003953A3 (en)	2002-02-28
NO20000293L (no)	2000-03-20
ATE269702T1 (de)	2004-07-15
KR20010022041A (ko)	2001-03-15
DE69824730T2 (de)	2005-07-14
PL338176A1 (en)	2000-10-09
JP2001513483A (ja)	2001-09-04
AR013240A1 (es)	2000-12-13
CA2297097C (en)	2009-04-07
IL134087A0 (en)	2001-04-30
AU8574398A (en)	1999-02-10
JP4521117B2 (ja)	2010-08-11
BR9810773A (pt)	2000-09-19
CA2297097A1 (en)	1999-01-28

Publication	Publication Date	Title
US6432986B2 (en)	2002-08-13	Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6491940B1 (en)	2002-12-10	Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches
US9302096B2 (en)	2016-04-05	Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation
EP0999839B1 (en)	2004-06-23	Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20010004644A1 (en)	2001-06-21	Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
US20220152394A1 (en)	2022-05-19	Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
US20050281751A1 (en)	2005-12-22	Directed intranasal administration of pharmaceutical agents
US20160030408A1 (en)	2016-02-04	Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
JP6200648B2 (ja)	2017-09-20	三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物
WO2001043733A2 (en)	2001-06-21	Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
JP2006515327A (ja)	2006-05-25	ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
EP1047412A1 (en)	2000-11-02	New use of local anaesthetics against vascular headaches
CZ2000215A3 (cs)	2000-11-15	Kompozice, kity a způsoby pro inhibici cerebrálních neurovaskuiárních poruch a svalové bolestí hlavy
Hosal et al.	1995	A rationale for the selection of nasal decongestants in lacrimal drainage surgery
Kumar	2023	Perspectives on Local Anesthetics in Medicine
MXPA00000705A (en)	2001-03-05	Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
Nguyen	2001	Topical Anesthetics and Local and Regional Blocks
KR20050016985A (ko)	2005-02-21	조합 치료법 및 이 치료법을 수행하기 위한 수단